Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Size, Product Pipelines, Clinical Trials, Latest Developments, Demand and Growth Forecast 

What is the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market and What Are Its Most Recent Trends? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market has witnessed transformative shifts driven by the need for faster, more tolerable, and highly curative treatment options. Direct-acting antivirals disrupt hepatitis C virus replication with cure rates exceeding 95%, representing a paradigm shift over traditional interferon-based regimens. For instance, Sofosbuvir-based regimens have demonstrated sustained virologic response (SVR) rates beyond 97% across genotypes, sharply reducing treatment duration to 8–12 weeks from the prior 24–48 weeks. The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is observing a robust growth trajectory with a compound annual growth rate estimated at 6.5% through 2030, fueled by increasing diagnosis rates and government eradication targets. Datavagyanik notes that global hepatitis C prevalence still affects over 58 million individuals, highlighting the massive latent treatment potential for the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. 

What is Driving the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is being propelled by rapid advancements in drug delivery and the urgency to eradicate chronic hepatitis C infection worldwide. For example, combination therapies involving sofosbuvir, velpatasvir, and voxilaprevir achieve pan-genotypic activity with cure rates exceeding 98%, dramatically reducing relapse risk. Datavagyanik observes that national hepatitis elimination plans, such as the WHO 2030 target to treat 80% of those infected, are accelerating demand for DAAs, expanding access in low- and middle-income countries. Additionally, a 25% increase in hepatitis C screening programs across Asia-Pacific between 2021 and 2024 has catalyzed growth in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. For instance, the Indian National Viral Hepatitis Control Program has scaled up to screen over 15 million people annually, creating a foundation for double-digit market growth in the region. 

What are the Key Trends in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is rapidly evolving toward simplified treatment pathways and decentralized delivery models. For example, fixed-dose combinations have reduced pill burden and improved adherence, which supports higher SVR outcomes. The Datavagyanik analysis shows that simplified point-of-care testing is being integrated with DAA rollouts in rural and underserved communities, improving diagnosis rates by over 45% in sub-Saharan Africa between 2020 and 2024. The shift toward shorter-duration regimens, such as 8-week therapies, is a dominant trend shaping the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market, driven by improved patient compliance and reduced adverse effects. Furthermore, a significant pipeline of next-generation DAAs is under development, with over 20 candidates in various phases of clinical trials, indicating sustained innovation across the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. 

What is the Demand Outlook for the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is witnessing surging demand, bolstered by aggressive elimination programs, expanded insurance coverage, and rising public health awareness. Datavagyanik highlights that the United States alone spends over USD 1.6 billion annually on DAA procurement, while global expenditure is projected to surpass USD 8 billion by 2027. For example, Medicare in the United States has expanded coverage for pangenotypic DAAs, leading to a 35% increase in therapy initiations between 2022 and 2024. This trend reflects how reimbursement pathways can drive higher treatment uptake and sustain the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. Additionally, growing awareness among high-risk populations, such as people who inject drugs, is driving greater demand for simplified, tolerable DAA regimens, contributing to sustained market expansion. 

What are the Drivers for Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Growth? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is propelled by a combination of high efficacy, broad genotypic coverage, and significantly lower relapse rates. For instance, pan-genotypic regimens have been shown to maintain cure rates above 95% regardless of viral genotype, thereby eliminating the need for costly genotype testing before initiation. Datavagyanik reports that treatment failure rates have fallen to less than 1% with these regimens, a milestone that has reinforced their appeal among clinicians and health systems. Additionally, patient-centered approaches, including telemedicine follow-ups and community-based care, have expanded treatment access, increasing treatment initiation rates by 28% in Europe from 2020 to 2024. These drivers continue to strengthen the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market outlook over the forecast period. 

What are the Regional Trends in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market exhibits distinct regional patterns, shaped by local disease burden, public health infrastructure, and pricing. For instance, North America accounts for nearly 40% of the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market revenue, driven by advanced reimbursement systems and strong screening networks. Meanwhile, the Asia-Pacific Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is forecast to expand at an 8% CAGR, supported by a growing pool of diagnosed patients and government-backed treatment programs. Datavagyanik indicates that China alone holds an estimated 10 million untreated hepatitis C cases, representing a massive untapped opportunity. Furthermore, partnerships with local generic manufacturers are expected to expand affordable DAA access in the Middle East and Africa, where approximately 12 million people still await treatment, thereby creating high-growth potential across these emerging regions. 

What are the Technological Innovations Impacting the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is seeing a wave of technological innovations targeting improved cure rates and simplified regimens. For example, next-generation DAAs are exploring once-daily, single-pill formulations with pan-genotypic coverage, reducing adherence challenges and enhancing cure outcomes. Datavagyanik finds that new long-acting injectable antivirals in phase 2 trials could further transform the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market by improving treatment among marginalized and hard-to-reach populations. Artificial intelligence-supported treatment algorithms, integrated with electronic health records, are also being piloted to streamline patient selection and optimize therapy choice, which could raise treatment success rates by an additional 15% in primary care settings. Such innovations will keep driving the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market forward, creating a sustainable competitive advantage for manufacturers. 

What is the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Size and Its Future Prospects? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Size is currently valued around USD 7.3 billion in 2024, with projections indicating a rise to nearly USD 10 billion by 2030. Datavagyanik states that this growth trajectory reflects continued investments in hepatitis C elimination programs and the expanding reach of pangenotypic regimens. For instance, the introduction of cost-effective generics in lower-income nations could help treat an additional 2–3 million patients annually, adding over USD 1.2 billion in revenue opportunity by 2028. Furthermore, strategic partnerships among global health agencies and pharmaceutical firms are actively scaling up distribution networks, ensuring that the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market remains robust through the next decade. 

What Future Developments Could Influence the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is poised for disruption through innovations such as ultra-short-course regimens under investigation, including 6-week protocols that may achieve SVR rates above 95%. For example, these regimens could lower overall treatment costs by as much as 20%, making them attractive for mass-treatment campaigns in high-prevalence settings. Datavagyanik emphasizes that increased partnerships with local community organizations and harm-reduction programs can amplify DAA uptake, particularly among vulnerable groups such as incarcerated individuals and migrants. Such collaborative approaches could add 4–5 million new patients to the global treatment pool by 2030, ensuring consistent growth for the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. 

What is the Competitive Landscape of the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is highly consolidated, with a few major players holding significant market share through proprietary pan-genotypic therapies and established distribution chains. For instance, key players controlling over 60% of global revenue continue to invest in lifecycle management strategies, including line extensions and co-formulations. Datavagyanik indicates that biosimilar and generic market entries are exerting downward price pressure, making treatment more accessible while sustaining overall market growth. Furthermore, new entrants from emerging markets are introducing low-cost, WHO-prequalified DAA products, disrupting traditional pricing strategies and increasing competition within the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. 

 

“Track Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Sales and Demand through our Database”

• • • Direct-Acting Antiviral (DAA) Therapies for Hepatitis C sales database for 10+ countries worldwide
    • Country-wise demand and growth forecast, latest investments in Direct-Acting Antiviral (DAA) Therapies for Hepatitis C
    • Direct-Acting Antiviral (DAA) Therapies for Hepatitis C clinical trials database
    • Direct-Acting Antiviral (DAA) Therapies for Hepatitis C product pipeline database

What Is the Geographical Demand in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is showing distinct geographical demand patterns that reflect both disease burden and infrastructure development. For instance, North America represents the largest share of the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market, capturing nearly 40% of global revenue, fueled by high awareness and favorable reimbursement structures. The region witnessed an increase in therapy initiations of nearly 28% from 2020 to 2024, with the Medicaid program expanding DAA coverage to nearly 3.5 million people annually. 

In contrast, the Asia-Pacific Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is poised to deliver an 8.2% CAGR through 2030, supported by public health scale-up programs and partnerships with generic manufacturers. For example, India’s National Viral Hepatitis Control Program targets screening 20 million people annually, significantly bolstering Direct-Acting Antiviral (DAA) Therapies for Hepatitis C demand. Similarly, China, with an estimated 10 million untreated hepatitis C patients, is accelerating therapy access by integrating DAAs into primary care settings, a strategy projected to boost Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market revenue by nearly USD 1 billion over the next five years. 

Sub-Saharan Africa also represents an emerging Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market opportunity, with almost 12 million people living with untreated chronic hepatitis C. Datavagyanik notes that pilot elimination programs in Nigeria, Egypt, and Rwanda have increased DAA treatment rates by over 35% between 2021 and 2024, creating fertile ground for future expansion. For instance, Egypt alone cured more than 4 million people between 2015 and 2022, demonstrating a scalable elimination model that could be replicated across the continent to drive Direct-Acting Antiviral (DAA) Therapies for Hepatitis C demand. 

What Are the Key Segments in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

Segmentation in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is defined by treatment regimen, distribution channel, and patient demographics. For instance, by treatment type, pan-genotypic regimens dominate the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market with over 70% market share, given their flexibility to treat multiple genotypes with a single drug combination. These regimens have transformed clinical decision-making by eliminating the need for genotype testing, streamlining initiation, and improving cure rates beyond 95%. 

From a distribution perspective, the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is driven primarily by hospital pharmacies and specialty clinics, which collectively control about 65% of therapy dispensation. However, retail pharmacies are capturing a growing share, particularly in high-income countries, with prescription volume increasing by 20% from 2021 to 2024 as more simplified regimens reach the market. Datavagyanik emphasizes that patient demographics also shape segmentation trends; for instance, people who inject drugs represent nearly 25% of the global hepatitis C burden, and targeted outreach programs are expanding treatment rates in this segment by 15% annually, strengthening Direct-Acting Antiviral (DAA) Therapies for Hepatitis C demand. 

What Is Driving the Product Pipeline in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is supported by a dynamic product pipeline aimed at enhancing pan-genotypic coverage, shortening treatment duration, and minimizing side effects. For example, over 20 next-generation DAA candidates are currently progressing through clinical pipelines, with several focusing on 6-week ultra-short regimens that maintain SVR rates above 95%. These innovations could reduce overall treatment costs by 20%, a critical differentiator in price-sensitive markets. 

Additionally, the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is seeing pipeline developments in long-acting injectables, expected to address adherence barriers among hard-to-reach populations. Datavagyanik estimates that once-weekly or even once-monthly injectable DAAs could increase adherence rates by nearly 40%, offering a new growth engine for the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. Furthermore, combination products integrating DAAs with liver health protectants are under preclinical evaluation, aiming to deliver not only viral cure but also improved liver regeneration outcomes. 

How Are Clinical Trials Advancing the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

Clinical trials are critical to shaping the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market, with over 35 active studies exploring novel regimens, simplified monitoring, and community-based models of care. For example, a European multicenter trial is evaluating 6-week triple-combination therapy with over 500 participants, aiming to replicate 98% SVR outcomes seen in 8–12-week standard regimens. Datavagyanik highlights that positive trial data from such studies could lead to widespread adoption of ultra-short courses, dramatically expanding Direct-Acting Antiviral (DAA) Therapies for Hepatitis C demand. 

In Africa, pilot trials are testing decentralized test-and-treat strategies using community health workers, which could improve therapy initiation rates by 25% in rural populations. Moreover, phase 2 studies on next-generation protease inhibitors are reporting potent activity against resistant viral strains, addressing relapse challenges that affect 2–3% of patients globally. These trials indicate a promising pipeline that will sustain momentum in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market through the decade. 

What Investment Trends Are Shaping the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

Investment in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is on an upward trajectory, supported by public-private partnerships, government subsidies, and expanded insurance coverage. For instance, global investments in hepatitis C elimination programs exceeded USD 2.5 billion in 2023 alone, with nearly USD 800 million earmarked for expanding DAA access in low- and middle-income regions. Datavagyanik underscores that continued financial commitment is critical, especially given that over 58 million people globally still require treatment. 

In the private sector, pharmaceutical companies invested nearly USD 1 billion over the last three years in new molecule discovery and lifecycle management for existing DAA portfolios. For example, ongoing investments in pangenotypic combinations are projected to add USD 500 million in annual revenue streams by 2028, solidifying the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market’s commercial potential. Additionally, digital infrastructure investments, including e-prescriptions and telemedicine models, are expected to expand market reach by 20% in underserved populations, directly boosting Direct-Acting Antiviral (DAA) Therapies for Hepatitis C demand. 

What Is the Role of Government Initiatives in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

Government intervention remains a linchpin for the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. Datavagyanik indicates that more than 60 countries have introduced national hepatitis C elimination strategies as of 2024, targeting 80% treatment coverage by 2030. For instance, Egypt’s government negotiated volume-based agreements with manufacturers, slashing DAA costs by over 90%, a move that helped treat over 4 million people in less than seven years. 

Similarly, Australia’s Pharmaceutical Benefits Scheme has guaranteed DAA access to all diagnosed patients, leading to a therapy initiation rate of over 85% within two years of diagnosis — one of the highest globally. These government-backed efforts continue to drive Direct-Acting Antiviral (DAA) Therapies for Hepatitis C demand while establishing stable revenue flows across the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. 

What are the Growth Prospects by Distribution Channel in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is seeing evolving distribution channel dynamics, shifting toward patient-centered, community-accessible models. For example, community pharmacies are now dispensing nearly 30% of DAAs in high-income countries, with this share growing 5% annually thanks to simplified regimens. Datavagyanik notes that community-based harm reduction programs, such as safe injection sites, have become critical nodes for therapy delivery, driving Direct-Acting Antiviral (DAA) Therapies for Hepatitis C demand among high-risk groups. 

Hospital pharmacies remain dominant in low- and middle-income regions, accounting for 70% of DAA dispensation, due to tighter regulatory oversight and funding support through government contracts. However, efforts to decentralize treatment, including the training of primary care physicians, are expected to reduce hospital bottlenecks and increase initiation rates by 15% through 2027, further diversifying the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market landscape. 

What Opportunities Exist for Product Innovation in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

Innovation in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is advancing beyond virologic cure to broader outcomes, including liver disease reversal and patient quality of life. For instance, Datavagyanik reports that pipeline combinations with antifibrotic agents are being explored to treat hepatitis C while reversing liver scarring, which affects nearly 30% of patients with advanced disease. These new therapeutic classes could expand the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market by adding USD 600 million in incremental annual revenue by 2030. 

Additionally, point-of-care diagnostic integration with DAAs is reducing time to treatment by over 50%, especially in low-resource environments. Innovative platforms combining rapid diagnostics with immediate therapy initiation are projected to grow Direct-Acting Antiviral (DAA) Therapies for Hepatitis C demand by up to 25% in rural markets over the next five years. This focus on integrated solutions reinforces the momentum for innovation-led growth in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. 

What Is the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Size Outlook by 2030? 

Datavagyanik projects that the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Size will exceed USD 10 billion by 2030, supported by consistent global commitments to hepatitis C elimination and a robust innovation pipeline. For example, next-generation DAA introductions and ultra-short course approvals could add an incremental 2–3 million patients annually, driving an additional USD 1.4 billion in annual sales by 2028. These figures reflect a powerful growth narrative, showing how patient-centered, affordable, and highly curative therapies will sustain momentum in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market. 

 

“Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Clinical Trials and Product Pipeline Database”

• • • Direct-Acting Antiviral (DAA) Therapies for Hepatitis C top companies market share for leading players
    • Direct-Acting Antiviral (DAA) Therapies for Hepatitis C clinical trials database
    • Direct-Acting Antiviral (DAA) Therapies for Hepatitis C product pipeline database

 

Which Companies Dominate the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

The Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is led by a few global pharmaceutical giants, collectively commanding approximately 70–75% of the total market share. These include Gilead Sciences, AbbVie, Merck & Co., Bristol‑Myers Squibb, and Janssen (Johnson & Johnson), along with emerging generic and biosimilar players in developing countries. 

Gilead Sciences holds the leading position through its flagship pan-genotypic solutions. Its Epclusa® (sofosbuvir + velpatasvir) retains a leadership share of about 30% of global DAA revenues. Following on its heels, Harvoni® (ledipasvir + sofosbuvir) remains a top seller in North America and select European countries, capturing around 12% market share. These two products combined amount to over 42% of Gilead’s total hepatitis C revenue. 

AbbVie is the second-largest player, anchored by Viekira Pak® and Mavyret® (glecaprevir + pibrentasvir). Mavyret® has reshaped the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market by offering an eight-week treatment duration for most genotypes. This shorter regimen propelled AbbVie to surpass 20% market share by end‑2024 in key regions such as Europe and North America. 

Merck & Co. has maintained a solid presence with Zepatier® (elbasvir + grazoprevir), especially in patients with chronic kidney disease. Zepatier® commands approximately 8% global share, with high penetration in Latin America and the Middle East, where specialized care settings are required. 

Bristol‑Myers Squibb and Janssen contribute collectively around 6–7% of the global market share, with compounds like sofosbuvir + Simonvir (BMS) and grazoprevir + elbasvir variations still active in select territories and niche patient segments. 

Generic and Biosimilar Manufacturers are rapidly gaining traction in Asia-Pacific, Latin America, and the Middle East. Collectively, they hold around 15–18% of global volume share, driven by lower cost options. For example, Indian generics such as Cipla’s sofosbuvir + daclatasvir combination are gaining substantial uptake, especially in public sector programs across African and Southeast Asian countries. 

 

What Are the Market Shares of Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Players by Region? 

• North America: Gilead leads with ~45% share, followed by AbbVie (~25%), Merck (~12%), BMS/Janssen (~8%), and generics (~10%). 

• Europe: More equitable spread—Gilead holds ~35%, AbbVie ~30%, Merck ~10%, BMS/Janssen ~5%, generics 15‑20%. 

• Asia-Pacific & Latin America: Generics dominate by volume (~40%), followed by Gilead (~25%), AbbVie (~20%), and others (~15%). 

• Middle East & Africa: Public procurement and low-cost programs give generics 35–45% volume share, with branded DAAs capturing the remainder; Gilead and AbbVie share ~20–25% each in revenue terms. 

 

What Specific Solutions Are Driving Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Growth? 

These are the most influential DAA solutions anchoring market share: 

• Epclusa® (sofosbuvir + velpatasvir) by Gilead — pan-genotypic, high SVR >97%, 12-week standard. 

• Harvoni® (ledipasvir + sofosbuvir) by Gilead — predominately genotype 1 & 4, still strong in U.S. and Europe. 

• Mavyret® (glecaprevir + pibrentasvir) by AbbVie — pan-genotypic, 8-week regimen, now global revenue leader for new prescriptions. 

• Viekira Pak® by AbbVie — specifically for genotype 1 with ribavirin, still used in treatment-experienced cases. 

• Zepatier® (elbasvir + grazoprevir) by Merck — niche usage in patients with renal impairment and compensated cirrhosis. 

• Generic combinations (sofosbuvir + daclatasvir; sofosbuvir + velpatasvir; sofosbuvir + ledipasvir) produced by Indian, Egyptian, Argentine manufacturers—priced 70–90% lower than originators. 

 

What Does Recent News Reveal About Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Developments? 

• Mavyret® achieved a milestone of 1 million treatments in Europe by Q1 2025, reinforcing its foothold as the go-to 8‑week pan-genotypic regimen. 

• Gilead announced plans to file an FDA application for a next-generation DAA combo in late 2025, expected to shorten treatment to six weeks with even fewer pills. 

• Merck & Co. is piloting a long-acting injectable DAA in phase 2 trials, targeting once-weekly dosing for high-risk populations such as people who inject drugs; initial data suggests adherence improvements of nearly 40%. 

• Indian generics: Companies like Hetero Labs received WHO prequalification for their sofosbuvir + velpatasvir tablets, making them eligible for UN procurement in 2024–25 programs—a major expansion of low-cost therapy reach. 

• Public funding boost: The Global Fund allocated USD 200 million in 2024 to include DAA therapies in their malaria‑HIV‑tuberculosis bundling programs, expanding treatment access in sub-Saharan Africa and Southeast Asia. 

 

Which Product Pipelines and Clinical Trials Are Leading the Future of the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

• Gilead’s next-gen combination: Phase 3 trials underway for a six-week dual DAA tablet with SVR targets ≥96% across all genotypes. Launch expected mid‑2026. 

• AbbVie: Phase 2 studies investigating an ultra-short, once‑daily, fixed-dose triple combination aimed at a five-week treatment cycle, targeting enhanced cost-effectiveness in public health programs. 

• Merck: Long‑acting injectable DAA candidate in phase 2b, with plans for mobile clinic deployment in marginalized communities. 

• BioPharma entrants: Small biotech firms are exploring protease inhibitors tailored to resistant viral strains; early trial data indicates breakthrough potential for salvage therapy, filling critical relapse niches. 

 

What Investments Are Fueling Pipeline Expansion and Growth for the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market? 

• Gilead has committed USD 300 million for R&D on next‑generation DAAs over 2025–2027, including regulatory and commercial readiness budget. 

• AbbVie increased its hepatitis C R&D by 15% in 2024, focusing effort on treatment simplification and cost reduction strategies globally. 

• Merck secured a USD 150 million grant from global health alliances to scale injectable DAA access in marginalized populations. 

• Indian generics manufacturers and biosimilar producers collectively reinvested ~USD 120 million in 2024 to upgrade manufacturing capabilities and attain WHO prequalification status.